Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Non-Current Debt (2020 - 2023)

C4 Therapeutics' Non-Current Debt history spans 4 years, with the latest figure at $8.6 million for Q1 2023.

  • For Q1 2023, Non-Current Debt fell 15.43% year-over-year to $8.6 million; the TTM value through Mar 2023 reached $8.6 million, down 15.43%, while the annual FY2022 figure was $9.2 million, 14.61% down from the prior year.
  • Non-Current Debt reached $8.6 million in Q1 2023 per CCCC's latest filing, down from $9.2 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $10.8 million in Q4 2021 to a low of $8.6 million in Q1 2023.
  • Average Non-Current Debt over 4 years is $9.9 million, with a median of $10.2 million recorded in 2022.
  • Peak YoY movement for Non-Current Debt: increased 7.2% in 2021, then decreased 15.43% in 2023.
  • A 4-year view of Non-Current Debt shows it stood at $10.1 million in 2020, then increased by 7.12% to $10.8 million in 2021, then dropped by 14.61% to $9.2 million in 2022, then fell by 6.24% to $8.6 million in 2023.
  • Per Business Quant, the three most recent readings for CCCC's Non-Current Debt are $8.6 million (Q1 2023), $9.2 million (Q4 2022), and $9.1 million (Q3 2022).